-

07:31:38 PM

AXNX Stock News

AXNX - Axonics Inc

03/07/23 6:00 AM

Nasdaq : AXNX

conferences

Axonics to Participate in the SUFU 2023 Winter Meeting

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine& Urogenital Reconstruction 2023 Winter Meeting, which is being held in Nashville from March 7-11.

RHEA-AI

neutral

03/01/23 4:01 PM

Nasdaq : AXNX

earnings

Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022. “This quarter’ s record results reflect the growing demand for our best-in-class incontinence products,”...

RHEA-AI

neutral

02/08/23 4:30 PM

Nasdaq : AXNX

conferencesearnings

Axonics to Report Fourth Quarter 2022 Financial Results on March 1

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.

RHEA-AI

neutral

01/31/23 6:00 AM

Nasdaq : AXNX

fda approval

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’ s fourth-generation rechargeable sacral neuromodulation system. Axonics plans to commercially launch the...

RHEA-AI

neutral

01/11/23 6:00 AM

Nasdaq : AXNX

earnings

Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance. “This quarter’ s record revenue result reflects the growing...

RHEA-AI

very positive

12/21/22 6:00 AM

Nasdaq : AXNX

conferences

Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Axonics is scheduled to present at 4:30 p.m. Pacific Time on Wednesday, January 11. A live webcast and...

RHEA-AI

neutral

12/13/22 6:00 AM

Nasdaq : AXNX

Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’ s fourth-generation rechargeable sacral neuromodulation system. “Since Axonics’ founding, delivering superior patient experiences has...

RHEA-AI

very positive

11/18/22 6:00 AM

Nasdaq : AXNX

conferences

Axonics® to Participate in the Piper Sandler Healthcare Conference

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to present at 11:00 a.m. Eastern Time. Axonics recently ranked No. 1 on the 2022 Financial Times...

RHEA-AI

neutral

11/16/22 11:06 AM

Nasdaq : AXNX

Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North...

RHEA-AI

positive

10/31/22 4:01 PM

Nasdaq : AXNX

earnings

Axonics® Reports Third Quarter 2022 Financial Results

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022. “This quarter’ s record revenue result reflects growing demand from physicians and their patients for our best-in-class...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

AXNX Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.axonicsmodulation.com
CeoRaymond Cohen
Security nameAxonics Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees517
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address26 Technology Dr
StateCalifornia
CityIrvine
Zip92618-2380
CountryUS
Phone19493966322

About Axonics Inc

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.